Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
2,854 total articles
Lumentum (LITE) is trading with momentum after a dramatic rerating driven by optical and photonic components used in AI data centers. The business mix, strong ROE, sizable float constraints and a meaningful short-interest backdrop create a favorable trade setup for the next 45 trading days. Valuation is rich, so the trade is tactical: enter on stre…
Alphabet is trading below key moving averages after a capex-driven pullback that scared short-term holders. Fundamentals - $73.3B free cash flow, $3.66T market cap, low leverage - support a long trade sized to a clear stop. Entry $305.00, target $350.00, stop $290.00 for a 180-trading-day trade that assumes capex converts into higher scale and dura…
ImmunityBio has a clearer regulatory path for ANKTIVA and expanding product revenue that justify a risk-on swing trade. The company still carries high valuation, negative cash flow, heavy short interest and legal overhangs. This trade targets upside into renewed regulatory progress while capping loss if momentum reverses.
Waterdrop (WDH) checks a rare box: profitable operations, accelerating revenue growth, and valuation below replacement cost. With a market cap near $647M, a P/E of ~9.3 and P/B under 1.0, the stock offers a measured swing opportunity—entry $1.77, target $2.20, stop $1.50—over a mid-term window of 45 trading days.
Celestica (CLS) is trading below its recent moving averages after a pullback tied to customer allocation headlines. The company has strong free cash flow ($398.2M), an attractive ROE (35%+), and a new SD6300 storage platform that positions it directly into AI/enterprise datacenter builds. This trade idea targets a mid-term swing capture to $360 wit…
Flowers Foods has been sold off on fears around dividends and shifting consumer behavior. The stock now trades at an attractive FCF multiple, sits near its 52-week low, and shows oversold technicals. This trade idea lays out an entry at $9.50, a stop at $8.75 and a mid-term target of $13.00, with clear catalysts and risk controls.
AeroVironment (AVAV) tumbled after a government stop-work order on its BADGER antenna contract. The pullback wiped out roughly 30% of market value and left the stock trading at $263 with a $13.1B market cap. We upgrade to BUY and recommend a tactical swing entry at $255.00 with a $360.00 target and a $225.00 stop. The company remains the leading UA…
Mixed U.K. inflation prints leave the Bank of England poised to stay data-dependent rather than pivot. For the iShares MSCI United Kingdom ETF (EWU) that implies upside in a steady reflation trade rather than a violent rally. Enter a measured long with a mid-term (45 trading days) horizon, defined stop and target.
Alkami (ALKT) looks wrongfully punished: revenue growth remains strong, the company is integrating a strategic $400M acquisition, and institutional analyst targets sit near $30. Technicals and short activity have driven price into oversold territory around $16.27. For traders who want a defined asymmetric trade tied to M&A speculation and mean-reve…
SQM is a low-risk way to trade a recovering lithium cycle. The company's diversified portfolio, completed Kwinana refinery, and a market cap of ~$20.2B give it scale. With lithium pricing showing early signs of recovery and Chinese supply disruptions resurfacing as a catalyst, SQM is the trade to own for a mid-term rebound while retaining downside …
<p>Celestica is trading below its 52-week high while showing strong profitability metrics and a manageable balance sheet. Market chatter about a roughly $1B increase in capital spending has been framed as a liability; I view it as a deliberate upgrade of capacity and capability tied to the SD6300 storage platform and AI/server demand. That investme…
ACM Research has accelerated its path back to meaningful revenue growth with 2026 guidance of $1.08–$1.175B and new product ramps. The market cap is roughly $4.2B, implying a P/E near the high-30s and EV/sales around 3.9x. That multiple is down from the frothier days but still leaves upside if product share gains and Oregon capacity investments tra…
Meta is seeing renewed conviction from big investors while its core advertising engine and Reality Labs investments are benefiting from AI-driven monetization. With a $1.62T market cap, high free cash flow, and manageable leverage, the risk/reward favors a long position here. This piece lays out an entry, stop, and target with catalysts, valuation …
PG&E (PCG) has moved from a 52-week low of $12.97 to a fresh 52-week high of $18.38, and the stock looks set to climb further as fundamentals improve and regulatory support materializes. Valuation is reasonable at roughly 15x earnings and 1.2x book, while multiple catalysts - including a DOE loan guarantee, activist interest, and accelerating elect…
Huntington Ingalls (HII) has lagged some peers in rerating, but recent program wins, robust free cash flow, and a cleaner balance sheet point to a constructive trade. I am upgrading HII to a long trade at $418.25 with a $475 target and a $380 stop, horizon 180 trading days. The risk/reward is attractive given a $16.4B market cap, $794M annual free …
Micron is trading near $400 after a year of dramatic DRAM/NAND repricing and accelerating revenue. Institutional allocators are rotating in, earnings momentum is visible, and balance-sheet metrics support risk-taking. This trade targets continued DDR5-driven pricing power and share gains into 2026 while protecting capital with a strict stop.
Axalta delivered solid operational metrics, including a record adjusted EBITDA quarter, but the stock has failed to rally. Valuation is middling (P/E ~19.6, EV/EBITDA ~9.2) while leverage (debt/equity 1.36) and a thin catalyst set leave limited upside. We recommend a tactical short for the mid term (45 trading days) with strict risk controls.
Microsoft looks priced for disappointment while Azure momentum may be reaccelerating. Technicals show oversold conditions (RSI ~31) and heavy short activity; fundamentals still strong with a ~$2.95T market cap, ~25x P/E and $77B free cash flow. This trade targets a mid-term rebound if cloud bookings/AI demand re-accelerate.
Adobe is a cash-generative software giant trading at a $107B market cap, but weakening technicals, elevated valuation multiples versus growth expectations, and a sector-wide 'SaaSpocalypse' narrative create a near-term setup for a valuation check. We lay out a swing (45 trading days) short: entry $260.48, stop $280.00, target $230.00, with explicit…
S&P Global (SPGI) has been caught in a sector-wide 'AI-phobia' selloff that looks disconnected from fundamentals. The company still generates roughly $5.46B of free cash flow, trades at a reasonable P/E near 28, and yields about 0.9%. Technicals are deeply oversold (RSI ~26) and short interest has been elevated—conditions that can accelerate a mean…
Lumentum (LITE) sits squarely at the intersection of photonics and data-center scale AI. The stock has run hard, but structural demand for optical interconnects and a thin supply pipeline make Lumentum a tactical long with defined risk controls. This trade idea lays out an entry at $580.00, stop at $520.00 and a primary target of $800.00 over a lon…
Dave & Buster's (PLAY) is executing a 'back to basics' turnaround under new leadership. The stock trades at $15.74 with an enterprise value to EBITDA of 5.2 and market cap of ~$546M. A disciplined entry at $15.50 with a $13 stop and $25 target offers asymmetric risk/reward if management stabilizes comps and margins.
Arista reported stronger-than-expected Q4 results and gave confident Q1 revenue guidance. With AI networking demand still accelerating and cloud customers shifting toward Ethernet, revenue growth should re-accelerate later in 2026. The trade here is a long position sized to a plan with a clear entry, stop and target tied to margin recovery and orde…
Aquestive plunged on an FDA letter that identified deficiencies in the Anaphylm NDA but confirmed review remains ongoing. The underlying biology, patents, and a recent funding line argue the program is viable; the stock now trades like a binary gamble. This trade idea lays out a mid-term, event-driven long with entry, stop, and target levels, and a…
Safran's aftermarket business is accelerating, margins are improving, and momentum indicators are bullish. With elevated short interest and constructive technicals, we upgrade to Strong Buy and recommend entering at $404.11 with a $480 target and a $368 stop. We expect the trade to play out over the next 180 trading days as recurring services and m…
